Lemaitre Vascular (LMAT) Cost of Revenue (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Cost of Revenue data on file, last reported at $18.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 1.6% year-over-year to $18.2 million in Q1 2026; TTM through Mar 2026 was $70.8 million, a 0.24% change from a year earlier, with the FY2025 full-year figure at $71.1 million, up 3.05% from the prior year.
• Cost of Revenue for Q1 2026 stood at $18.2 million, down from $18.3 million in the prior quarter.
• Over the last five years, Cost of Revenue for LMAT reached as high as $19.3 million in Q2 2025 and fell as low as $13.6 million in Q1 2022.
• Historically, Cost of Revenue has averaged $16.6 million across 5 years, with a median of $16.8 million in 2024.
• Across the five-year window, Cost of Revenue grew 26.09% in 2023 and decreased 14.45% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $14.9 million in 2022, then grew by 4.82% to $15.6 million in 2023, then climbed by 9.66% to $17.1 million in 2024, then advanced by 6.63% to $18.3 million in 2025, then decreased by 0.59% to $18.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $18.2 million in Q1 2026, $18.3 million in Q4 2025, and $15.1 million in Q3 2025.